ISRCTN14123846Active, not recruitingPhase 3
An open-label, multicenter extension study to evaluate the long-term safety and tolerability of faricimab administered in patients previously enrolled in studies sponsored by F. Hoffmann-La Roche Ltd
F. Hoffman-la Roche0 sites350 target enrollmentStarted: August 6, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 350
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Previous enrollment in and completion of any faricimab parent study without study or study drug discontinuation.
- •2. Enrolled in the mainland of China
- •3. Signed Informed Consent Form
- •4. Ability and willingness to comply with the study protocol, in the investigator's judgment
Exclusion Criteria
- •1. Pregnant or breastfeeding, or intending to become pregnant during the study or within 28 days after the final ITV injection of faricimab
- •2. Women of childbearing potential must have a negative urine pregnancy test result within 28 days prior to initiation of study treatment. If the urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.EUCTR2004-000047-18-SEBiogen Idec Ltd.1,900
Active, not recruiting
Not Applicable
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.Type 2 diabetes MellitusMedDRA version: 7Level: lowClassification code 10012613EUCTR2005-004268-21-HUF. Hoffmann-La Roche Ltd370
Active, not recruiting
Not Applicable
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.EUCTR2005-004268-21-DEF. Hoffmann-La Roche Ltd370
Active, not recruiting
Not Applicable
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.Type 2 diabetes MellitusMedDRA version: 7Level: lowClassification code 10012613EUCTR2005-004268-21-GBF. Hoffmann-La Roche Ltd370
Active, not recruiting
Phase 1
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Alagille Syndrome (ALGS) or Progressive Familial Intrahepatic Cholestasis (PFIC)Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)MedDRA version: 17.1 Level: SOC Classification code 10010331 Term: Congenital, familial and genetic disorders System Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 17.1 Level: PT Classification code 10053870 Term: Alagille syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-000906-20-GBShire Human Genetic Therapies Inc999,999